LA JOLLA, CA, April 30, 2024 – Enlaza Therapeutics, the first covalent biologic platform company, today announced a $100 million Series A financing. The financing will be used to further...
Arthur Klausner to be a featured speaker at CED Biotech Forum: Trends in Exit Strategies.
News | 06. 18. 2007
© 2024 Pappas Capital, LLC. ALL RIGHTS RESERVED.